L Muller

Biography

Mr. Muller has almost 30 years of pharmaceutical industry experience where he served startup-to-large multinational companies.  Prior to joining Milestone, he led the marketing team at Exact Sciences Corporation with accountability for developing and implementing all aspects of Exact Sciences’ marketing plans to transform and grow the business in its existing markets while playing a strategic role in product and market expansion activity. Before that Mr. Muller led the thrombosis franchise at Daiichi Sankyo with US responsibility for the launch and P&L of novel cardiovascular blood-thinning drugs Effient® (prasugrel) and Savaysa® (edoxaban). Prior to Daiichi Sankyo, he was Vice President of Marketing and Healthcare Outcomes at CV Therapeutics, where he played a foundational role in the transition of the company from an R&D to a commercial organization and oversaw the launch of Ranexa® (ranolazine), a first-in-class treatment for chronic angina. Before joining CV Therapeutics, Mr. Muller spent six years with Merck & Co., Inc. in various sales and marketing positions including product management as part of the hypertension and heart failure business group. He also served as a consultant for Arthur D. Little, Inc, for five years completing technology-based consulting assignments for a large number of biotechnology, pharmaceutical, and fine chemical clients. Mr. Muller received a BS in both chemical engineering and life sciences and his MS in chemical engineering from the Massachusetts Institute of Technology. He earned his MBA from the Harvard Graduate School of Business Administration. Mr. Muller has almost 30 years of pharmaceutical industry experience where he served startup-to-large multinational companies.  Prior to joining Milestone, he led the marketing team at Exact Sciences Corporation with accountability for developing and implementing all aspects of Exact Sciences’ marketing plans to transform and grow the business in its existing markets while playing a strategic role in product and market expansion activity. Before that Mr. Muller led the thrombosis franchise at Daiichi Sankyo with US responsibility for the launch and P&L of novel cardiovascular blood-thinning drugs Effient® (prasugrel) and Savaysa® (edoxaban). Prior to Daiichi Sankyo, he was Vice President of Marketing and Healthcare Outcomes at CV Therapeutics, where he played a foundational role in the transition of the company from an R&D to a commercial organization and oversaw the launch of Ranexa® (ranolazine), a first-in-class treatment for chronic angina. Before joining CV Therapeutics, Mr. Muller spent six years with Merck & Co., Inc. in various sales and marketing positions including product management as part of the hypertension and heart failure business group. He also served as a consultant for Arthur D. Little, Inc, for five years completing technology-based consulting assignments for a large number of biotechnology, pharmaceutical, and fine chemical clients. Mr. Muller received a BS in both chemical engineering and life sciences and his MS in chemical engineering from the Massachusetts Institute of Technology. He earned his MBA from the Harvard Graduate School of Business Administration.

Research Interest

Buisness Management